Second-line hormonal therapy with the enzalutamid in patients with castrate-resistant prostate cancer

Prostate cancer (PC) is an actual problem of modern oncourology due to the continuing high rates of this disease morbidity and mortality. Despite improvements in diagnostic techniques, incidence of common forms of the disease remain to be high. Metastatic castrate-resistant prostate cancer (mCRPC) is a disease with an extremely poor prognosis, in which standard methods of hormonal treatment are ineffective. Heterogeneity of CRPC patient population requires differentiated approach to the administration of therapy based on the availability of various prognostic factors. Not so long ago chemotherapy with docetaxel was the main treatment for this group of patients. Second-line hormonal therapy was introduced into clinical practice in 2011 with the advent of new drugs aimed at the complete suppression of testosterone production. Enzalutamid, a new drug for second-line hormonal therapy, has essentially different mechanism of action. It is able to block androgen recep￾tors selectively and disrupt translocation of the signal from the receptor into the cell and into the cell nucleus. Large randomized trials that studied the effectiveness of this drug allowed to register it for clinical use, including our country. An article presents a review of the literature on clinical trials devoted to the use of a drug in CRPC patients. 

1. Злокачественные новообразования в России в 2014 г. (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2016. [Malignant tumors in Russia in 2014 (morbidity and fatality). Ed. by: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Мoscow, 2016. (In Russ.)].

2. Матвеев В.Б. Онкоурология. Роль гормонотерапии у больных локальным и местно-распространенным раком предстательной железы при использовании радикальных методов лечения. 2005;(2):54–7. [Маtevev V.B. The role of hormone therapy at patients with local and locally spread prostate cancer, using the definitive therapy. Onkourologiya = Оncourology 2005;(2):54–7. (In Russ.)].

3. Garnick M.B. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993;118:804–18.

4. Per-Anders A. Revolutions in the management of hormone-refractory prostate cancer. Eur Urol 2003;2:1–2.

5. EAU Guidelines 2016.

6. Матвеев В.Б., Бабаев Э.Р. Факторы прогноза выживаемости больных распространенным раком предстательной железы, получающих гормонотерапию. Онкоурология 2011;(2):78–83. [Маtveev V.B., Babaev E.R. Survival forecast factors of patients with spread prostate cancer, receiving hormone therapy. Onkourologiya = Оncourology 2011;(2):78–83. (In Russ.)].

7. Oh W. Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer 2000;88:3015–21.

8. Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12.

9. de Bono J.S., Oudard S., Ozguroglu M. et al; Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147–54. DOI: 10.1016/S0140-6736(10)61389-X.

10. de Bono J.S., Logothetis C.J., Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995–2005. DOI: 10.1056/NEJMoa1014618.

11. Ryan C.J., Smith M.R., de Bono J.S. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138–48. DOI: 10.1056/NEJMoa1209096.

12. Attard G., Belldegrun A.S., de Bono J.S. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 2005;96(9):1241–6.

13. Tran, C., Ouk S., Clegg N.J. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324: 787–90.

14. Chen C.D., Welsbie D.S., Tran C. et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33–9.

15. Kelly W.K., Slovin S., Scher H.I. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol Clin North Am 1997;24:421–31.

16. Teutsch G., Goubet F., Battmann T. et al. Nonsteroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor. J. Steroid Biochem. Mol Biol 1994;48:111–9.

17. Van Dort M.E., Robins D.M., Wayburn B. Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl) – 5-oxo-2-thioxo-1- imidazolidinyl] – 2-iodobenzonitrile as a high-affinity nonsteroidal androgen receptor ligand. J Med Chem 2000;43:3344–7.

18. Jung M.E., Ouk S., Yoo D. et al. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem 2010;53:2779–96. DOI: 10.1021/jm901488g.

19. Hodgson M.C., Astapova I., Cheng S. et al. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem 2005;280:6511–9.

20. Baek S.H., Ohgi K.A., Nelson C.A. et al. Ligand- specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proc Natl Acad Sci USA 2006;103:3100–5.

21. Efstathiou E., Titus M., Wen S. et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol 2015;67:53–60. DOI: 10.1016/j.eururo.2014.05.005.

22. Guerrero J., Alfaro I.E., Gomez F. et al. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate 2013;73:1291–305. DOI: 10.1002/pros.22674.

23. Morris M.J., Basch E.M., Wilding G. et al. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer 2009;7:51–7. DOI: 10.3816/CGC.2009.n.009.

24. Bambury R.M., Scher H.I. Enzalutamide: Development from bench to bedside. Urol Oncol 2015;33:280–8. DOI: 10.1016/j.urolonc.2014.12.017.

25. Scher H.I., Beer T.M., Higano C.S. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 2010;375:1437–46. DOI: 10.1016/S0140-6736(10)60172-9.

26. Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367: 1187–97.

27. Bennett D., Gibbons J.A., Mol R. et al. Validation of a method for quantifying enzalutamide and its major metabolites in human plasma by LC–MS/MS. Bioanalysis 2014;6:737–44. DOI: 10.4155/bio.13.325.

28. Shore N.D., Chowdhury S., Villers A. et al. Effcacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomized, double-blind, phase 2 study. Lancet Oncol 2016;13:2016. DOI: 10.1016/S1470-2045(15)00518-5.

29. Beer T.M., Armstrong A.J., Rathkopf D.E. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424–33. DOI: 10.1056/NEJMoa1405095.

30. Fizazi K., Scher H.I., Miller K. et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration- resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 2014;15:1147–56. DOI: 10.1016/S1470-2045(14)70303-1.

31. Sternberg C.N., de Bono J.S., Chi K.N. et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol 2014;25:429–34. DOI: 10.1093/annonc/mdt571.

32. Saad F., de Bono J., Shore N. et al. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. Eur Urol 2014;67:223–30. DOI: 10.1016/j.eururo.2014.08.025.